Associate Professor | Group Leader
Associate Professor White is a Principal Research Fellow (Group Leader) and NHMRC Senior Research Fellow (SRFA) (2017-2021) at QIMR Berghofer, where he leads a group researching cellular processes in neurodegenerative diseases with a focus on developing new human cell models of neurodegeneration. He received his PhD from Murdoch University (1996) followed by post-doctoral appointments at the University of Melbourne (1996-2001) and Imperial College, London (2001-2003). In 2003, he was appointed at the University of Melbourne (2003-2016) and moved to QIMR Berghofer in 2016. He has over 150 research publications, obtained over $12 million in competitive research funding and co-founded a start-up biotech company, Procypra Therapeutics. His research has led to the development of first-in-class metal-drugs as a new therapeutic approach to neurodegeneration, leading to a novel copper-based metal-drug currently in clinical trials for motor neuron disease and Parkinson’s disease.
2016-current: Principal Research Fellow (Group Leader)
2017-2021: NHMRC Senior Research Fellow
2004-2016: Principal Research Fellow (Associate Professor), Department of Pathology, University of Melbourne
2003: Senior Research Officer, Florey Institute of Neuroscience and Mental Health
2001-2002: Research Associate, Imperial College of Medicine, London, UK
1996-2001: Senior Research Fellow, Department of Pathology, University of Melbourne
The Cellular and Molecular Neurodegeneration laboratory investigates the cause and potential treatments for brain diseases including dementia (Alzheimer’s disease), motor neuron disease (amyotrophic lateral sclerosis) and Parkinson’s disease. These disorders, collectively known as neurodegenerative diseases, are a growing health issue in Australia and worldwide with few treatment options available. In order to gain a better understanding of these diseases and develop new therapeutic approaches, the research team is currently developing new human brain cell culture methods for microglia, brain endothelial cells, organoids (mini-brains), and olfactory (nasal) cells.
The Lab is utilising these new 2D and 3D human brain cell models to understand brain disease pathways, and the impact of environmental factors such as air pollution, SARS-CoV-2, and bushfire smoke on brain health. The team has also established platforms for drug screening to identify potential new therapeutics for treatment of brain diseases.
1996: PhD Murdoch University, Australia
1991: BSc (Hons) Murdoch University, Australia